Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study

Area of Science:

• Immunology
• Dermatology
• Rheumatology

Background:

• Behçet's syndrome is characterized by oral ulcers often resistant to standard treatments.
• Apremilast, an oral phosphodiesterase-4 inhibitor, modulates inflammatory pathways.
• There is a need for alternative therapeutic agents for Behçet's syndrome oral ulcers.

Purpose of the Study:

• To evaluate the efficacy of apremilast in treating oral ulcers in patients with Behçet's syndrome.
• To assess the impact of apremilast on pain associated with oral ulcers.
• To explore apremilast's effect on other disease manifestations and quality of life.

Main Methods:

• A phase 2, multicenter, placebo-controlled study.
• 111 patients with Behçet's syndrome and at least two oral ulcers were randomized.
• Patients received apremilast (30 mg twice daily) or placebo for 12 weeks, followed by an extension phase.

Main Results:

• Apremilast significantly reduced the mean number of oral ulcers at 12 weeks compared to placebo (0.5 vs. 2.1).
• Apremilast demonstrated a significantly greater reduction in oral ulcer pain scores than placebo.
• Gastrointestinal side effects like nausea and diarrhea were more frequent with apremilast.

Conclusions:

• Apremilast is effective for treating oral ulcers in Behçet's syndrome.
• Further research is needed to assess long-term efficacy and safety.
• The study provides preliminary evidence for apremilast as a treatment option for Behçet's syndrome oral ulcers.